Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

977.00 -7.64 (-0.78%)
Streaming Delayed Price Updated: 1:59 PM EDT, May 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
30 31 32 33 34 35 36 37 Next >
Stocks That Hit 52-Week Highs On Tuesday
Before 10 a.m. ET on Tuesday, 55 companies set new 52-week highs. Points of Interest: Apple (NASDAQ:AAPL) was the largest company by market cap to set a new 52-week... 
Via Benzinga
Novartis Shares Two Year Beovu Data From Diabetic Macular Edema Studies
Novartis AG (NYSE: NVS) has reported data from two Phase 3 trials assessing Beovu (brolucizumab) 6 mg versus Regeneron Pharmaceuticals Inc's (NASDAQ: REGN... 
Via Benzinga
Understanding Regeneron Pharmaceuticals's Unusual Options Activity
On Friday, shares of Regeneron Pharmaceuticals (NASDAQ:REGN 
Via Benzinga
3 Growth Stocks Cathie Wood Is Selling That Are Still Worth Buying
Wood might regret trimming her positions in these great growth stocks. 
Via The Motley Fool
Large Cap Biopharma Stocks provide Growth and Value
The S&P 500 Healthcare Index was up 0.53% and biotech still lags in healthcare yet Large Cap Biopharma is doing well YTD. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Regeneron's Antibody Cocktail Authorized for Preventing COVID: Why It's Not a Big Deal for the Stock
The biotech's EUA expansion for REGEN-COV will probably provide only an incremental sales boost. 
Via The Motley Fool
Exposures COVID-19
eBay And AMD Lead The QQQ Friday
U.S. indices traded flat for much of Friday’s session as concerns over the COVID-19 Delta variant continues to cause market uncertainty. The Invesco QQQ Trust Series 1... 
Via Benzinga
Exposures COVID-19
Vaccine Stocks Fly On Booster Shot OK, But Their Run Could Be Short-Lived
Vaccine stocks popped Friday after the FDA authorized a third dose of their Covid shots from some immunocompromised people. 
Via Investor's Business Daily
Exposures Product Safety
What Rinvoq's Positive News Means for AbbVie
If the drug can overcome JAK inhibitor-class concerns, it could capture share in the growing atopic dermatitis market. 
Via The Motley Fool
Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases
Ocular Therapeutix Inc (NASDAQ: OCUL) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have terminated the option and license agreement collaboration. The... 
Via Benzinga
Regeneron Pharmaceuticals Inc (REGN) Q2 2021 Earnings Call Transcript
REGN earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Exicure Shares Interim Cavrotolimod Data From Early-Stage Trial In Solid Tumor Patients
Exicure Inc (NASDAQ: XCUR) has reported interim results from Phase 1b/2 trial evaluating cavrotolimod (AST-008) in patients with advanced or metastatic solid... 
Via Benzinga
Delta, Lambda Covid Variants Still Weighing On Market Despite Positive Earnings Reports
The market is still in a waiting mode, with a lot hinging on tomorrow’s jobs report. Predictions of a volatile, choppy week in the equity markets did not disappoint on... 
Via Benzinga
Sanofi - Regeneron's Libtayo/Chemo Treatment Improves Overall Survival First-Line Lung Cancer
The Phase 3 trial of Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo in combination with platinum-doublet chemotherapy... 
Via Benzinga
Regeneron Beats Street Estimates Big In Q2 As COVID-19 Antibody Boosts Topline, Cuts FY21 R&D Spend Outlook
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $25.80 per share for the second quarter, beating the $17.69 estimate. It clocked revenue of $5.1 billion,... 
Via Benzinga
Exposures COVID-19
Regeneron Pharmaceuticals: Q2 Earnings Insights
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) moved higher by 0.0% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share... 
Via Benzinga
Regeneron Earnings Obliterate Views; Biotech Giant Tops Buy Point
Regeneron earnings and sales boomed far above forecasts. The biotech giant rose above a buy point. 
Via Investor's Business Daily
3 Biotech Stocks That Could Make You Richer in August (and Beyond)
All three have blockbuster products already on the market. 
Via The Motley Fool
Market Briefing For Tuesday, Aug. 3
We do see Tuesday turnaround as a rebound from Monday's just modest fade. Again our wildcard continues to be Covid; and the 'presumed' dovish Fed as relates to 'tapering'. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
10 Biggest Price Target Changes For Monday
Raymond James raised Edwards Lifesciences Corporation (NYSE: 
Via Benzinga
FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis
Following the June update that 
Via Benzinga
Exposures COVID-19 Product Safety
Market Briefing For Monday, Aug. 2
We're 'not' in a global financial crisis; but we are failing the 'synchronized global recovery', due to the worldwide pandemic. 
Via Talk Markets
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Regeneron - Sanofi's Dupixent Improves Itch, Hives In Inflammatory Skin Disease Patients
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) have announced topline results from Phase 3 trial evaluating Dupixent (... 
Via Benzinga
Is This Mid-Cap Biotech Stock a Buy Now?
This mid-cap growth stock could be a long-term winner. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
Market Briefing For Thursday, July 29
Disarming SARS-CoV-2 with pharmaceutical drugs is the 'holy grail' to end the COVID-19 panic, and generally eliminate the panic pressures for vaccines. 
Via Talk Markets
Exposures COVID-19
3 Things About Regeneron That Smart Investors Know
The biotech's COVID-19 antibody cocktail made headlines last year, but there's a bigger story here. 
Via The Motley Fool
Topics Government
Exposures COVID-19 Political
3 Reasons Caribou Biosciences Could Be the Best Gene-Editing Stock for Your Portfolio
The company has a pedigree and a novel approach that could put it at the top of the CRISPR heap. 
Via The Motley Fool
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
Maravai Lifesciences Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Maravai Lifesciences sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
< Previous 1 2
...
30 31 32 33 34 35 36 37 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.